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Introduction:
Although permanent hypoparathyroidism after thyroid or parathyroid surgery rarely happens in general practice, it is a difficult clinical problem. Long-term parathyroid hormone (PTH) therapy is rarely applied nowadays because PTH has very short half life (2-4 min.) and must be injected daily [1 -3] . Gene therapy for hypoparathyroidism through gene transfer to skeletal cells or stem cell has been previously reported [4 -6] . Although long-term gene therapy of hypoparathyroidism with stem cells recombined with parathyroid hormone gene and retroviral vectors has been reported previously [6] , we conducted this study to optimize the gene therapy of hypoparathyroidism with a stem cell-line without viral vectors.
Animals:
Male Spraque-Dawley rats (about 300 gm) were used throughout this experiment.
The animals were purchased from the National Science Council animal center and housed in Chang Gung Memorial Hospital at Kaohsiung, Taiwan. This study was performed in accordance with the guidelines provided by the experimental animal laboratory and approved by the animal care and use committee. The rats could access to food and water ad libitum and were housed in a controlled environment at a temperature of 24±1℃, a humidity of 55±5%, and a circadian light rhythm of 12 hr.
Three groups were designed as followed: parathyroidectomy treated with the 3 TheraCyte encapsulated 4x10 7 cells, which were transfected with PTH (1-34) cDNA as the study group (group A, n=9); parathyroidectomy treated with the subcutaneous injection of 4x10 7 cells, which were transfected with PTH (1-34) cDNA as the subcutaneous injection group (group B, n=9); and parathyroidectomy treated with nothing as the control group (group C, n=10).
Results
All rats in group A survived well with normal appetites and activities. Two of 9 rats in group B and also 3 of 10 rats in group C died as a result of exhaustion within one month after parathyroidectomy. Serum levels of calcium in group A were significantly higher than in both groups B and C (all ≦ 0.003) ( Table 1) . Serum levels of phosphorus in group A were significantly lower than in both groups B and C (all p ≦ 0.002) ( Table 2 ). Serum levels of PTH (1-34) in group A were significantly higher than in both groups B (p = 0.004) and C (p = 0.003) ( Table 3 ). In group A, both serum calcium and PTH (1-34) levels were significantly higher at 2, 3, and 4 months post-treatment than at baseline (0-month) (all p ≦ 0.022) ( Table 1 and Table 3 ). In group A, serum phosphorus levels were lower at 1, 2, 3, and 4 months post-treatment than at baseline (all p < 0.001) ( Table 2 ). Hematoxylin and eosin staining showed live cells in the TheraCyte (Fig. 1A) , and immunohistochemical staining demonstrated 
Discussion:
Mesenchymal stem cells have been used as a carrier for conditionally replicating adenoviruses to target metastatic breast cancer in vivo [7] or as a vehicle for oncolytic adenoviruses [8, 9] . Mesenchymal stem cells-mediated gene delivery of bone morphogenetic protein-2 also has been reported to induce bone formation and to heal bone fracture [10, 11] . We used the C3H/10T1/2 cell-line, which was established in 1972 from 14-and 17-day old C3H mouse embryos [12] , as the gene therapy of After implantation of the TheraCyte-encapsulated 4x10 7 C3H/10T1/2 cells, which were recombined with PTH (1-34) cDNA, we found that the live cells could secrete PTH (1-34) as documented in our study of live human parathyroid cells [13] .
Serum calcium and PTH (1-34) levels increased significantly 2 months later and could be maintained for up to 4 months. Serum calcium and PTH (1-34) levels in the study group were significantly higher than in the subcutaneous injection group and also higher than in the control group. Serum levels of phosphorus decrease significantly 1 month later and could be maintained for up to 4 months. Serum phosphorus levels were significantly lower in the study group than in the subcutaneous injection group and also lower than in the control group. 
Materials and Methods:
Plasmid DNA:
The plasmid carrying full-length human PTH ( Live cells containing PTH (1-34) cDNA at the density of 4x10 7 were loaded into the TheraCyte, using the centrifugation loading method according to the users' manual (TheraCyte Inc. Irvine, CA). In group A, after parathyroidectomy, the TheraCyte-encapsulated 4 x 10 7 live stem cells containing PTH (1-34) cDNA, were implanted to the subcutaneous tissue of rats' back. In group B, after parathyroidectomy, live stem cells containing PTH (1-34) cDNA at the density of 4x10 7 were injected directly to the subcutaneous tissue of rats' xiphoid processes. In group C, nothing was given after parathyroidectomy. Under sodium pentothal anesthesia, a longitudinal skin incision was made at the anterior part of neck. The right and left parathyroid glands were exposed and removed under microscopic examination (x16). After this procedure the rats were returned to the animal center, to recover until the experiment.
Immunohistochemical staining with PTH (1-34) antibody:
Four months after implantation, the TheraCyte-encapsulated 4x10 7 cells was removed from the rats' back and sent for the histological examination. Four months after subcutaneous injection of 4x10 7 cells (group B), the rats' skin and subcutaneous at xiphoid process was excised for the histological examination. After formalin-fixation, the TheraCyte and tissues were deparaffinized in xylene and dehydrated in a graded ethanol series. An endogenous peroxidase was quenched with 3% hydrogen peroxide in methanol. After incubation of the tissue with rabbit anti-human parathyroid hormone (1-34) serum (dilated 1:6000, Phoenix Pharmaceuticals, Belmont, CA), horseradish peroxidase (Zymed Laboratories/Invitrogen, San Francisco, CA) was added, and after a wash step,
